VIVUS Receives U.S. Food and Drug Administration Approval for Improved Formulation of PANCREAZE® with a 36-Month Shelf Life
February 05, 2020 07:30 ET
|
VIVUS, Inc.
CAMPBELL, Calif., Feb. 05, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) (“VIVUS”), a biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved...
New Data Further Demonstrate Effectiveness of VIVUS’ Qsymia as a Weight Management Tool
January 07, 2020 07:30 ET
|
VIVUS, Inc.
-Data published in Journal of General Internal Medicine show that patients using Qsymia and other weight loss tools, lost at least 5% of body weight loss compared with those not using Qsymia- ...
VIVUS to Present at Biotech Showcase on January 13, 2020
January 02, 2020 07:30 ET
|
VIVUS, Inc.
CAMPBELL, Calif., Jan. 02, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company, today announced that John Amos, Chief Executive Officer, will present at...
VIVUS Adopts Stockholder Rights Plan
December 31, 2019 07:30 ET
|
VIVUS, Inc.
CAMPBELL, Calif., Dec. 31, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company, today announced that on December 30, 2019 its board of directors adopted...
VIVUS Announces New Data Supporting the Safety and Efficacy of Qsymia® in Adolescents with Obesity
December 18, 2019 07:30 ET
|
VIVUS, Inc.
-Data published in Diabetes, Obesity and Metabolism demonstrate that Qsymia provides statistically significant weight loss compared with placebo over an 8 week period, provide basis for ongoing 56...
VIVUS to Present at Piper Jaffray 31st Annual Healthcare Conference on December 3, 2019
November 25, 2019 07:30 ET
|
VIVUS, Inc.
CAMPBELL, Calif., Nov. 25, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company, today announced that John Amos, Chief Executive Officer at VIVUS, will...
New Clinical Data Demonstrate VIVUS’ Qsymia® is Effective at Reducing Binge Eating in Patients with Binge-Eating Disorder or Bulimia Nervosa
November 20, 2019 07:30 ET
|
VIVUS, Inc.
-Data published in International Journal of Eating Disorders show patients in the Qsymia group had 75% decrease in binge day frequency compared with 19% for placebo- CAMPBELL, Calif., Nov. 20,...
VIVUS Reports Third Quarter 2019 Financial Results
November 05, 2019 16:05 ET
|
VIVUS, Inc.
CAMPBELL, Calif., Nov. 05, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (NASDAQ: VVUS) (the “Company”), a specialty pharmaceutical company committed to the development and commercialization of innovative...
VIVUS Announces Departures of Eric W. Roberts and Allan L. Shaw from Board of Directors
October 28, 2019 07:30 ET
|
VIVUS, Inc.
CAMPBELL, Calif., Oct. 28, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company, announced today that Eric W. Roberts and Allan L. Shaw have resigned from...
VIVUS to Host Third Quarter Business Update and Financial Results Conference Call on Tuesday, November 5, 2019
October 22, 2019 07:30 ET
|
VIVUS, Inc.
CAMPBELL, Calif., Oct. 22, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) today announced that it will report financial results and provide a business update for the third quarter of 2019 after...